京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002020 京新药业

已收盘 05-17 15:00:00

{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":11.92,"timestamp":1715929437000,"preClose":11.91,"halted":0,"volume":8709600,"delay":0,"floatShares":656000000,"shares":861000000,"eps":0.7421,"marketStatus":"已收盘","marketStatusCode":5,"change":0.01,"latestTime":"05-17 15:00:00","open":11.93,"high":11.98,"low":11.76,"amount":103000000,"amplitude":0.0185,"askPrice":11.93,"askSize":477,"bidPrice":11.92,"bidSize":76,"shortable":0,"etf":0,"ttmEps":0.7421,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716168600000},"adr":0,"adjPreClose":11.91,"symbolType":"stock","openAndCloseTimeList":[[1715909400000,1715916600000],[1715922000000,1715929200000]],"highLimit":13.1,"lowLimit":10.72,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"pbRate":1.8,"roa":"--","roe":"3.06%","epsLYR":0.72,"committee":-0.388106,"marketValue":10263000000,"floatMarketCap":7824000000,"peRate":16.062525,"changeRate":0.0008,"turnoverRate":0.0133,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-05-20。"},"requestUrl":"/m/hq/s/002020/wiki","defaultTab":"wiki","newsList":[{"id":"2435755106","title":"京新药业(002020.SZ)2023年度权益分派：每10股派3元 股权登记日5月23日","url":"https://stock-news.laohu8.com/highlight/detail?id=2435755106","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435755106?lang=zh_cn&edition=full","pubTime":"2024-05-16 19:05","pubTimestamp":1715857556,"startTime":"0","endTime":"0","summary":"智通财经APP讯，京新药业(002020.SZ)发布公告，公司2023年年度权益分派方案为：以公司现有总股本为基数，向全体股东每10股派3.00元人民币现金(含税)，本次权益分派股权登记日为：2024年5月23日，除权除息日为：2024年5月24日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1122155.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433738619","title":"京新药业：公司暂无扩大睿泰投资的计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2433738619","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433738619?lang=zh_cn&edition=full","pubTime":"2024-05-08 00:00","pubTimestamp":1715097638,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业05月07日在投资者关系平台上答复投资者关心的问题。投资者：公司投资的上海睿泰，现在占比12.4%是第五大股东，未来会不会对上海睿泰扩大投资比例让其成为子公司，拓展再生生物业务，完善医药+医疗的布局。公司暂无扩大睿泰投资的计划。目前沙溪制药的一部分品种的生产，正有序地向内蒙新产区转移。公司安宫牛黄丸已于2022年下半年上市，目前暂未在京东和天猫平台旗舰店内销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800000002.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432131106","title":"京新药业公布国际专利申请：“配体-寡核苷酸共轭物及用于该共轭物的接头”","url":"https://stock-news.laohu8.com/highlight/detail?id=2432131106","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2432131106?lang=zh_cn&edition=full","pubTime":"2024-05-04 04:31","pubTimestamp":1714768262,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示京新药业公布了一项国际专利申请，专利名为“配体-寡核苷酸共轭物及用于该共轭物的接头”，专利申请号为PCT/CN2023/125626，国际公布日为2024年4月25日。专利详情如下：图片来源：世界知识产权组织今年以来京新药业已公布的国际专利申请1个。结合公司2023年年报财务数据，2023年公司在研发方面投入了4.01亿元，同比增9.23%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050400003337.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431832830","title":"京新药业：针对京诺宁，公司目前仍然以国内市场为重点，时机合适也将推动海外市场拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2431832830","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431832830?lang=zh_cn&edition=full","pubTime":"2024-04-29 19:02","pubTimestamp":1714388574,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业04月29日在投资者关系平台上答复投资者关心的问题。公司会围绕京诺宁新机制带来的疗效提升，尽快推动市场拓展和其他各项工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900025215.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430871877","title":"京新药业获得发明专利授权：“一种左乙拉西坦的制备方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2430871877","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430871877?lang=zh_cn&edition=full","pubTime":"2024-04-27 02:47","pubTimestamp":1714157248,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示京新药业新获得一项发明专利授权，专利名为“一种左乙拉西坦的制备方法”，专利申请号为CN202211010560.6，授权日为2024年4月26日。今年以来京新药业新获得专利授权2个，较去年同期减少了33.33%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700005868.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430669440","title":"太平洋：给予京新药业买入评级，目标价位18.42元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430669440","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430669440?lang=zh_cn&edition=full","pubTime":"2024-04-25 13:50","pubTimestamp":1714024237,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司周豫,刘哲涵近期对京新药业进行研究并发布了研究报告《Q1业绩超预期，盈利能力改善》，本报告对京新药业给出买入评级，认为其目标价位为18.42元，当前股价为11.44元，预期上涨幅度为61.01%。考虑公司院内集采影响出清，院外市场提升空间大，创新药持续提供增量，维持“买入”评级，维持目标价18.42元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500024739.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430492313","title":"京新药业（002020）2024年一季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2430492313","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430492313?lang=zh_cn&edition=full","pubTime":"2024-04-25 06:11","pubTimestamp":1713996661,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期京新药业发布2024年一季报。根据财报显示，本报告期中京新药业营收净利润同比双双增长，盈利能力上升。截至本报告期末，公司营业总收入10.61亿元，同比上升10.44%，归母净利润1.71亿元，同比上升13.23%。营收分析方面，公司最新一期年度报表的现金流为正，经营性现金流和利润相匹配。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500011843.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429481028","title":"平安证券：给予京新药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2429481028","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429481028?lang=zh_cn&edition=full","pubTime":"2024-04-24 16:37","pubTimestamp":1713947841,"startTime":"0","endTime":"0","summary":"平安证券股份有限公司叶寅,韩盟盟,臧文清近期对京新药业进行研究并发布了研究报告《24Q1业绩重回长期增长轨道，盈利能力持续优化》，本报告对京新药业给出增持评级，当前股价为11.24元。　　平安观点：　　公司24Q1收入端恢复较快增长，利润端重回长期增长轨道。公司首个1类新药，适用于失眠患者短期治疗的地达西尼胶囊于24年3月底正式上市销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400033329.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429164266","title":"京新药业(002020.SZ)发布一季度业绩，净利润1.71亿元，同比增长13.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429164266","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429164266?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:21","pubTimestamp":1713867707,"startTime":"0","endTime":"0","summary":"智通财经APP讯，京新药业(002020.SZ)披露2024年第一季度报告，报告期公司实现营收10.61亿元，同比增长10.44%;归母净利润1.71亿元，同比增长13.23%;扣非净利润1.57亿元，同比增长14.3%。基本每股收益0.2元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107685.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429164862","title":"京新药业：作为一款创新药，地达西尼具有特殊的新作用机制及其带来的疗效提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2429164862","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429164862?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:04","pubTimestamp":1713866676,"startTime":"0","endTime":"0","summary":"作为一款创新药，地达西尼具有特殊的新作用机制及其带来的疗效提升。公司除了化药地达西尼之外，中成药当中的滋肾宁神丸、润肠宁神膏和补血宁神片都具有安神的功效。地达西尼主要用于失眠患者的短期治疗。地达西尼由于其创新的作用机制，在临床试验阶段显现出包括长期服用戒断反应等方面的较好的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300035523.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429928926","title":"京新药业与九州通医药集团达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2429928926","media":"证券时报","top":-1,"share":"https://www.laohu8.com/m/news/2429928926?lang=zh_cn&edition=full","pubTime":"2024-04-22 20:52","pubTimestamp":1713790333,"startTime":"0","endTime":"0","summary":"证券时报e公司讯，据京新药业消息，4月22日，京新药业与九州通医药集团举行战略合作签约仪式，京新药业董事长吕钢与九州通集团副董事长刘登攀签署《战略合作框架协议》，双方将深化拓展合作领域，实现共赢发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042220521587a17751&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042220521587a17751&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2423451164","title":"京新药业(002020.SZ)发布2023年度业绩，净利润6.19亿元，下降6.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2423451164","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2423451164?lang=zh_cn&edition=full","pubTime":"2024-03-29 18:21","pubTimestamp":1711707660,"startTime":"0","endTime":"0","summary":"京新药业发布2023年年度报告，报告期内，公司实现营业收入39.99亿元，同比增长5.79%。实现归属于上市公司股东的净利润6.19亿元，同比下降6.55%。基本每股收益为0.72元。其中成品药收入23.26亿元，同比增长4.98%;原料药收入9.56亿元，同比增长9.60%;医疗器械收入6.37亿元，同比增长1.39%，主营业务保持了平稳增长。受折旧摊销和研发、管理费用增加影响，全年实现归母净利润6.19亿元，同比下降6.55%;实现扣非净利润5.33亿元，同比下降11.60%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-29/doc-inapytuu0477276.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-29/doc-inapytuu0477276.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2390347243","title":"兴欣新材：公司和陶氏、巴斯夫、东进、京新药业、默克等知名企业建立了紧密的战略合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2390347243","media":"全景网","top":-1,"share":"https://www.laohu8.com/m/news/2390347243?lang=zh_cn&edition=full","pubTime":"2023-12-11 17:49","pubTimestamp":1702288140,"startTime":"0","endTime":"0","summary":"兴欣新材首次公开发行股票并在主板上市网上路演于2023年12月11日（星期一）14:00-17:00在全景路演举行。　　路演现场，兴欣新材董事长叶汀表示，公司和陶氏、巴斯夫、东进、京新药业、默克、华峰集团、壳牌、诺力昂等知名企业建立了紧密的战略合作关系。　　了解本次路演提问，请点击：https://rs.p5w.net/html/141199.shtml\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2023-12-11/doc-imzxruey1129706.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2023-12-11/doc-imzxruey1129706.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","stockEarnings":[{"period":"1week","weight":-0.0124},{"period":"1month","weight":0.1595},{"period":"3month","weight":0.155},{"period":"6month","weight":-0.1516},{"period":"1year","weight":-0.1562},{"period":"ytd","weight":-0.0629}],"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","perCapita":"33079股","boardName":"医药制造业","registeredCapital":"86102万元","compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.0326},{"period":"1year","weight":-0.0435},{"period":"ytd","weight":0.0602}],"survey":"　　浙江京新药业股份有限公司主要从事化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品为心脑血管药物、神经系统药物、消化系统药物、呼吸系统药物、泌尿生殖系统药物、喹诺酮类抗感染原料药、他汀类原料药、精神类原料药、定制化医用显示器和HMI、标准化医用显示器及医疗影像解决方案。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。","serverTime":1716022067925,"listedPrice":10.05,"stockholders":"167174人(较上一季度增加443.71%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}